RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+4.03%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.54B
AUM Growth
+$6.54B
(-1.1%)
Cap. Flow
+$38.9M
Cap. Flow
% of AUM
0.59%
Top 10 Holdings %
Top 10 Hldgs %
52.67%
Holding
82
New
10
Increased
17
Reduced
8
Closed
14
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$100M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$65.3M |
| 3 |
GE HealthCare
GEHC
|
$42M |
| 4 |
BBNX
Beta Bionics, Inc. Common Stock
BBNX
|
$40.4M |
| 5 |
uniQure
QURE
|
$35.6M |
Top Sells
| 1 |
Bruker
BRKR
|
$145M |
| 2 |
Axsome Therapeutics
AXSM
|
$132M |
| 3 |
89bio
ETNB
|
$40.1M |
| 4 |
Dyne Therapeutics
DYN
|
$36.9M |
| 5 |
Alkermes
ALKS
|
$22.2M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Madrigal Pharmaceuticals
MDGL
$9.76B
| $660M | 10.1% | 1,993,687 | – | – |
|
2
argenx
ARGX
$43.6B
| $399M | 6.1% | 673,497 | – | – |
|
3
PTC Therapeutics
PTCT
$3.92B
| $381M | 5.83% | 7,483,127 +90,000 | +1% | +$4.59M |
|
4
Natera
NTRA
$23.1B
| $367M | 5.61% | 2,593,546 +223 | +0% | +$31.5K |
|
|
5
Axsome Therapeutics
AXSM
$6.05B
| $341M | 5.21% | 2,922,729 -1,128,636 | -28% | -$132M |
|
6
Akero Therapeutics
AKRO
$3.74B
| $300M | 4.59% | 7,419,340 +559,517 | +8% | +$22.6M |
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $277M | 4.23% | 5,719,415 +220,870 | +4% | +$10.7M |
|
8
Avidity Biosciences
RNA
$5.99B
| $258M | 3.95% | 8,746,926 +814,056 | +10% | +$24M |
|
9
Penumbra
PEN
$10.6B
| $231M | 3.53% | 862,770 +320 | +0% | +$85.6K |
|
10
Insmed
INSM
$28.8B
| $230M | 3.52% | 3,014,558 | – | – |
|
|
11
Alkermes
ALKS
$4.78B
| $227M | 3.48% | 6,884,698 -673,137 | -9% | -$22.2M |
|
12
Stryker
SYK
$150B
| $220M | 3.36% | 590,221 | – | – |
|
|
VRNA
13
Verona Pharma
VRNA
$9.16B
| $181M | 2.77% | 2,848,800 +1,027,781 | +56% | +$65.3M |
|
14
Merus
MRUS
$4.98B
| $175M | 2.68% | 4,169,393 | – | – |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $170M | 2.61% | 3,316,032 +79,483 | +2% | +$4.08M |
|
16
Immunocore
IMCR
$1.62B
| $144M | 2.21% | 4,869,798 | – | – |
|
17
Acadia Pharmaceuticals
ACAD
$4.38B
| $142M | 2.17% | 8,540,117 -165,384 | -2% | -$2.75M |
|
18
Rocket Pharmaceuticals
RCKT
$354M
| $118M | 1.8% | 17,687,772 | – | – |
|
19
RadNet
RDNT
$5.52B
| $115M | 1.76% | 2,317,582 +339,000 | +17% | +$16.9M |
|
20
Masimo
MASI
$7.59B
| $114M | 1.74% | 683,294 | – | – |
|
21
Zai Lab
ZLAB
$3.68B
| $113M | 1.73% | 3,136,680 +627,561 | +25% | +$22.7M |
|
22
Cytokinetics
CYTK
$4.23B
| $109M | 1.67% | 2,721,158 | – | – |
|
23
Establishment Labs
ESTA
$1.2B
| $105M | 1.61% | 2,583,887 +14,200 | +0.6% | +$579K |
|
24
Apogee Therapeutics
APGE
$2.17B
| $101M | 1.55% | 2,712,097 | – | – |
|
|
25
Intuitive Surgical
ISRG
$170B
| $100M | 1.53% | +202,456 | New | +$100M |
|